03.01.11
Clondalkin Group has acquired the Printed Components business of Catalent Pharma Solutions. Terms of the transaction were not disclosed, and closing is subject to receipt of regulatory approval. The unit generated approximately $100 million in annual sales of secondary packaging products out of its four facilities in the U.S., Puerto Rico and Ireland.
Clondalkin and Catalent will enter into a long-term supply agreement which ensures that Catalent will continue to be able to provide services to its customers. Barry Russell, president of Catalent’s Medication Delivery Solutions business, said, “We are pleased that Clondalkin Group has agreed to acquire the business.We believe that Clondalkin will continue to build upon the business’ legacy of excellent service and high quality.We also believe the commitment Clondalkin Group has demonstrated to the industry aligns well with our approach of tailoring unique product supply solutions for our customers.”
Norbert McDermott, Clondalkin Group’s chief executive officer, said, “In the U.S., the acquisition further expands our leading position offering full-service dedicated pharmaceutical and healthcare production facilities at nine locations in NC, NJ, IN, CT and Puerto Rico. In Europe, combining Catalent’s cartons expertise with our inserts, leaflets and labels expertise presents excellent business development and cross-selling opportunities for our nine pharmaceutical and healthcare production facilities in Ireland, Spain, the UK and Poland.”
Headquartered in Amsterdam, Clondalkin has annual sales of more than $1.1 billion; after this acquisition, pharmaceutical and healthcare activities will account for approximately $340 million in annual revenues.
Click here to learn more about Catalent
Clondalkin and Catalent will enter into a long-term supply agreement which ensures that Catalent will continue to be able to provide services to its customers. Barry Russell, president of Catalent’s Medication Delivery Solutions business, said, “We are pleased that Clondalkin Group has agreed to acquire the business.We believe that Clondalkin will continue to build upon the business’ legacy of excellent service and high quality.We also believe the commitment Clondalkin Group has demonstrated to the industry aligns well with our approach of tailoring unique product supply solutions for our customers.”
Norbert McDermott, Clondalkin Group’s chief executive officer, said, “In the U.S., the acquisition further expands our leading position offering full-service dedicated pharmaceutical and healthcare production facilities at nine locations in NC, NJ, IN, CT and Puerto Rico. In Europe, combining Catalent’s cartons expertise with our inserts, leaflets and labels expertise presents excellent business development and cross-selling opportunities for our nine pharmaceutical and healthcare production facilities in Ireland, Spain, the UK and Poland.”
Headquartered in Amsterdam, Clondalkin has annual sales of more than $1.1 billion; after this acquisition, pharmaceutical and healthcare activities will account for approximately $340 million in annual revenues.
Click here to learn more about Catalent